RWJMS Institute for Neurological Therapeutics and Department of Neurology, Rutgers - Robert Wood Johnson Medical School, 683 Hoes Lane West, Room 180, Piscataway, NJ, 08854, USA.
Current address: Sanyou Biopharmaceuticals Co., Ltd., 3rd Floor, Building 6B-C, No. 188 Xinjunhuan Road, Minhang District, Shanghai, 201114, China.
Neurotherapeutics. 2021 Oct;18(4):2529-2540. doi: 10.1007/s13311-021-01130-6. Epub 2021 Oct 25.
α-Synuclein is a key protein in the pathogenesis of Parkinson's disease as it accumulates in fibrillar form in affected brain regions. Misfolded α-synuclein seeds recruit monomeric α-synuclein to form aggregates, which can spread to anatomically connected brain regions, a phenomenon that correlates with clinical disease progression. Thus, downregulating α-synuclein levels could reduce seeding and inhibit aggregate formation and propagation. We previously reported that microRNA-7 (miR-7) protects neuronal cells by downregulating α-synuclein expression through its effect on the 3'-untranslated region of SNCA mRNA; however, whether miR-7 blocks α-synuclein seeding and propagation in vivo remains unknown. Here, we induced miR-7 overexpression in the mouse striatum unilaterally by infusing adeno-associated virus 1 (AAV-miR-7) followed by inoculation with recombinant α-synuclein preformed fibrils (PFF) a month later. Compared with control mice injected with non-targeting AAV-miR-NT followed by PFF, AAV-miR-7 pre-injected mice exhibited lower levels of monomeric and high-molecular-weight α-synuclein species in the striatum, and reduced amount of phosphorylated α-synuclein in the striatum and in nigral dopamine neurons. Accordingly, AAV-miR-7-injected mice had less pronounced degeneration of the nigrostriatal pathway and better behavioral performance. The neuroinflammatory reaction to α-synuclein PFF inoculation was also significantly attenuated. These data suggest that miR-7 inhibits the formation and propagation of pathological α-synuclein and protects against neurodegeneration induced by PFF. Collectively, these findings support the potential of miR-7 as a disease modifying biologic agent for Parkinson's disease and related α-synucleinopathies.
α-突触核蛋白是帕金森病发病机制中的关键蛋白,因为它在受影响的大脑区域中以纤维形式积累。错误折叠的α-突触核蛋白作为种子招募单体α-突触核蛋白形成聚集体,这些聚集体可以传播到解剖学上连接的大脑区域,这一现象与临床疾病进展相关。因此,下调α-突触核蛋白水平可以减少种子形成并抑制聚集体的形成和传播。我们之前报道过,microRNA-7(miR-7)通过其对 SNCA mRNA 3'-非翻译区的作用下调α-突触核蛋白表达来保护神经元细胞;然而,miR-7 是否在体内阻断α-突触核蛋白的种子形成和传播仍不清楚。在这里,我们通过单侧脑内注射腺相关病毒 1(AAV-miR-7)诱导小鼠纹状体中的 miR-7 过表达,一个月后再接种重组α-突触核蛋白原纤维(PFF)。与注射非靶向性 AAV-miR-NT 后再注射 PFF 的对照组小鼠相比,预先注射 AAV-miR-7 的小鼠纹状体中的单体和高分子量α-突触核蛋白水平较低,纹状体和黑质多巴胺神经元中的磷酸化α-突触核蛋白水平也较低。相应地,预先注射 AAV-miR-7 的小鼠黑质纹状体通路的变性程度较轻,行为表现较好。α-突触核蛋白 PFF 接种引起的神经炎症反应也明显减弱。这些数据表明,miR-7 抑制病理性α-突触核蛋白的形成和传播,并防止 PFF 诱导的神经退行性变。总之,这些发现支持 miR-7 作为帕金森病和相关α-突触核蛋白病的疾病修饰生物制剂的潜力。